Date Closed

February 15, 2018

Lead Office

Québec City

Value

14.38 Million CAD

On February 15, 2018, Immunovaccine Inc., (“Immunovaccine”) announced the closing of the C$14.375 million bought deal public offering (the “Offering”) of common shares of Immunovaccine (the “Common Shares”), including exercise of the over-allotment option in full. An aggregate of 7,187,500 Common Shares were issued at a price of $2.00 per Common Share. The Offering was conducted by a syndicate of underwriters led by Echelon Wealth Partners Inc. and including National Bank Financial Inc. and Bloom Burton Securities Inc.

Immunovaccine intends to use the net proceeds of the Offering to continue to advance its pipeline and conduct a Phase 1 basket trial in up to five indications to be identified, for research and development, working capital, and for general corporate purposes. The Offering will also allow Immunovaccine to continue maximizing the value in its technology and expanding its world-class immuno-oncology clinical program.

Immunovaccine is a TSX-listed clinical stage vaccine and immunotherapy company, headquartered in Nova Scotia. Immunovaccine is developing T cell-activating cancer immunotherapies based on its patented immuno-stimulating technology platform, which provides controlled and prolonged delivery of immuno-stimulating agents to the immune system.

McCarthy Tétrault LLP advised Immunovaccine with a team led by Philippe Leclerc that included Myreille Gilbert and Annie Poirier-Simard.